GlassScriptPhysician profile
Wesley J Henson
NPI 1235380155
$5,865.39
in general payments reported to CMS, 2019-2025
26 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,016 · 2022: $835 · 2023: $1,190 · 2024: $1,433 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,836.15 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $789.59 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $700.90 | 2021-2025 | |
| Lilly USA, LLC | $675.68 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $586.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $472.73 | 2021-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.23 | 2021-2024 | Xifaxan |
| Mylan Specialty L.P. | $99.97 | 2022-2024 | Yupelri, Yupelri |
| Lundbeck LLC | $76.43 | 2022-2023 | Vyepti |
| Exact Sciences Corporation | $64.89 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $58.46 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $57.15 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.46 | 2024 | |
| Viatris Specialty LLC | $35.93 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.82 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.64 | 2024 | Jardiance, Tradjenta |
| Agile Therapeutics, INC. | $21.98 | 2021 | |
| Amarin Pharma, INC. | $20.21 | 2021 | |
| Dexcom, INC. | $19.21 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $17.64 | 2025 | Inspire |
| Kerecis Limited | $17.11 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Merck Sharp & Dohme LLC | $14.46 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.00 | 2022 | |
| Genentech USA, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Henson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.